Regeneron Pharmaceuticals, Inc.-Product Pipeline Review-2015

Regeneron Pharmaceuticals, Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07048CDB
  • |
  • Pages: 86
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Regeneron Pharmaceuticals, Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'Regeneron Pharmaceuticals, Inc.-Product Pipeline Review-2015', provides an overview of the Regeneron Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Regeneron Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of Regeneron Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Regeneron Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Regeneron Pharmaceuticals, Inc.'s pipeline products

Reasons To Buy

Evaluate Regeneron Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Regeneron Pharmaceuticals, Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Regeneron Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Regeneron Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Regeneron Pharmaceuticals, Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Regeneron Pharmaceuticals, Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Regeneron Pharmaceuticals, Inc. Snapshot 6

Regeneron Pharmaceuticals, Inc. Overview 6

Key Information 6

Key Facts 6

Regeneron Pharmaceuticals, Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

Regeneron Pharmaceuticals, Inc.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Combination Treatment Modalities 12

Pipeline Products-Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Regeneron Pharmaceuticals, Inc.-Pipeline Products Glance 15

Regeneron Pharmaceuticals, Inc.-Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

Regeneron Pharmaceuticals, Inc.-Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

Regeneron Pharmaceuticals, Inc.-Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Regeneron Pharmaceuticals, Inc.-Drug Profiles 20

aflibercept (recombinant) 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

alirocumab 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

dupilumab 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

sarilumab 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

ziv-aflibercept (recombinant) 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

evinacumab 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

rinucumab 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

trevogrumab 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

REGN-19081909 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

(aflibercept + nesvacumab) 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

nesvacumab 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

REGN-1154 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

REGN-1193 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

REGN-1400 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

REGN-1979 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

REGN-2222 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

REGN-2810 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

REGN-1001 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Regeneron Pharmaceuticals, Inc.-Pipeline Analysis 51

Regeneron Pharmaceuticals, Inc.-Pipeline Products by Target 51

Regeneron Pharmaceuticals, Inc.-Pipeline Products by Route of Administration 53

Regeneron Pharmaceuticals, Inc.-Pipeline Products by Molecule Type 54

Regeneron Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action 55

Regeneron Pharmaceuticals, Inc.-Recent Pipeline Updates 57

Regeneron Pharmaceuticals, Inc.-Dormant Projects 78

Regeneron Pharmaceuticals, Inc.-Discontinued Pipeline Products 79

Discontinued Pipeline Product Profiles 79

dapiclermin 79

enoticumab 79

nesvacumab 79

REGN-2009 79

REGN-728 79

REGN-846 80

rilonacept (recombinant) 80

Regeneron Pharmaceuticals, Inc.-Company Statement 81

Regeneron Pharmaceuticals, Inc.-Locations And Subsidiaries 83

Head Office 83

Other Locations & Subsidiaries 83

Regeneron Pharmaceuticals, Inc.-Key Manufacturing Facilities 84

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86

List of Tables

Regeneron Pharmaceuticals, Inc., Key Information 6

Regeneron Pharmaceuticals, Inc., Key Facts 6

Regeneron Pharmaceuticals, Inc.-Pipeline by Indication, 2015 8

Regeneron Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 10

Regeneron Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 11

Regeneron Pharmaceuticals, Inc.-Combination Treatment Modalities in Pipeline, 2015 12

Regeneron Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 13

Regeneron Pharmaceuticals, Inc.-Partnered Products/ Combination Treatment Modalities, 2015 14

Regeneron Pharmaceuticals, Inc.-Pre-Registration, 2015 15

Regeneron Pharmaceuticals, Inc.-Phase III, 2015 16

Regeneron Pharmaceuticals, Inc.-Phase II, 2015 17

Regeneron Pharmaceuticals, Inc.-Phase I, 2015 18

Regeneron Pharmaceuticals, Inc.-Preclinical, 2015 19

Regeneron Pharmaceuticals, Inc.-Pipeline by Target, 2015 52

Regeneron Pharmaceuticals, Inc.-Pipeline by Route of Administration, 2015 53

Regeneron Pharmaceuticals, Inc.-Pipeline by Molecule Type, 2015 54

Regeneron Pharmaceuticals, Inc.-Pipeline Products by Mechanism of Action, 2015 56

Regeneron Pharmaceuticals, Inc.-Recent Pipeline Updates, 2015 57

Regeneron Pharmaceuticals, Inc.-Dormant Developmental Projects,2015 78

Regeneron Pharmaceuticals, Inc.-Discontinued Pipeline Products, 2015 79

Regeneron Pharmaceuticals, Inc., Other Locations 83

Regeneron Pharmaceuticals, Inc., Subsidiaries 83

Regeneron Pharmaceuticals, Inc., Key Manufacturing Facilities 84

List of Figures

Regeneron Pharmaceuticals, Inc.-Pipeline by Top 10 Indication, 2015 8

Regeneron Pharmaceuticals, Inc.-Pipeline by Stage of Development, 2015 10

Regeneron Pharmaceuticals, Inc.-Monotherapy Products in Pipeline, 2015 11

Regeneron Pharmaceuticals, Inc.-Partnered Products in Pipeline, 2015 13

Regeneron Pharmaceuticals, Inc.-Pipeline by Top 10 Target, 2015 51

Regeneron Pharmaceuticals, Inc.-Pipeline by Top 10 Route of Administration, 2015 53

Regeneron Pharmaceuticals, Inc.-Pipeline by Top 10 Molecule Type, 2015 54

Regeneron Pharmaceuticals, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 55

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

Current R&D Portfolio of Regeneron Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc. - Key Therapeutics; Regeneron Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Regeneron Pharmaceuticals, Inc. - News; Regeneron Pharmaceuticals, Inc. - Latest Updates; Regeneron Pharmaceuticals, Inc. - Pipeline; Regeneron Pharmaceuticals, Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 97065
Site License
USD 3000 INR 194130
Corporate User License
USD 4500 INR 291195



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]